2016 TOP STORIES: Lilly Alzheimer’s drug fails in high-stakes trial
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
Clinical Trials
Articles
Pharmaceutical firm plans $10.4M in new equipment, 60 jobs
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
At Eli Lilly, tears, heartbreak and renewed determination
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
Wall Street analysts jumping on Lilly train
For more than two years, Eli Lilly and Co. has pushed the message that the worst days are over and a brighter future is just around the corner. Now, finally, Wall Street is starting to believe.
Confluence Pharmaceuticals lands $1.3M in venture capital
Indianapolis-based Elevate Ventures said it made the investment through the 21st Century Research & Technology Fund, which is reserved for Indiana companies.
Lilly drug for Alzheimer’s gets fast-tracked by FDA
Named AZD3293, the drug belongs to a novel class of drugs that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
Lilly angles for arthritis blockbuster
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.
Lilly’s heart study sets up showdown with Novo’s Victoza
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Experimental osteoporosis drug bests Lilly’s Forteo in study
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Alzheimer’s trials offer little certainty for investors, patients
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
Lilly buoyed by string of positive results from drug trials
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Potential Alzheimer’s drug further backs protein hypothesis
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
Lilly to delay U.S., EU approval of basal insulin
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
Lilly rheumatoid arthritis drug meets goals in final-stage trial
If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.
Recent wins worth $4B to Lilly market value
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Lilly says new insulin fares better than rival’s in late-stage tests
The Indianapolis-based drugmaker said Thursday that peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
Biotech comeback: Eli Lilly making renewed push in lucrative field it once pioneered
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
Indy startup has rare disease in its sights
Founders of Chondrial Therapeutics believe that if further testing validates their treatment for Friedreich’s ataxia, it could be a blockbuster with annual sales topping $1 billion.
Roche drug trial backs Lilly on Alzheimer’s findings
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
Regenstrief taps Deloitte to pick up more health care industry clients
With federal health research funding in decline, Indianapolis-based Regenstrief Institute Inc. wants to make up the difference by serving pharmaceutical companies, medical device makers, health insurers and hospital systems.